建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
Oneness announces the information about the investor's conference of 2022 Q3.
SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by FDA to proceed with a Ph1 study
Oneness submitted an IND to US FDA for a phase I clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)
Oneness submitted an IND to US FDA for a phase I clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)
US FDA notified today that 510(k) Premarket Notification of Bonvadis, the wound care topical cream was substantially equivalent.
The Company's 2022Q2 consolidated financial statements have been approved by the Board of Directors
The Drug Administration of Vietnam has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon
Oneness announces the information about the investor's conference of 2022 Q2.
The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations
Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.
The Annual General Shareholders' Meeting approved the removal of non-competition restriction on the newly-elected director.
By-election of one director of the board in 2022 shareholders' meeting
Oneness announce the important resolutions of the 2022 Annual General Shareholders' Meeting
The Company's 2022Q1 consolidated financial statements have been approved by the Board of Directors
Oneness received the notification by the international CRO on the unblinded data of FB825 Phase 2a study in moderate-to-severe atopic dermatitis in the U.S.
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?